Attached files

file filename
EX-99.2 - EX-99.2 - AMERICAN VANGUARD CORPd234405dex992.htm
8-K - FORM 8-K - AMERICAN VANGUARD CORPd234405d8k.htm

Exhibit 99.1

LOGO

FOR IMMEDIATE RELEASE

AMERICAN VANGUARD REPORTS SECOND QUARTER & MID-YEAR 2016 RESULTS

Strong Improvement in Revenue and Earnings Performance

Newport Beach, CA – August 2, 2016 – American Vanguard Corporation (NYSE:AVD), today announced financial results for the second quarter and six-month period ended June 30, 2016.

Fiscal 2016 Second Quarter Financial Highlights – versus Fiscal 2015 Second Quarter Results

 

  Net sales increased 9% to $72.7 million from $66.5 million

 

  Net income increased to $3.2 million from $0.8 million

 

  Earnings per diluted share increased to $0.11 from $0.03

Fiscal 2016 Six Month Financial Highlights – versus Fiscal 2015 Six Month Results

 

  Net sales increased 7% to $142.2 million from $133.1 million

 

  Net income increased to $6.0 million from $0.8 million

 

  Earnings per diluted share increased to $0.21 from $0.03

Note: Further details are available in the financial schedules attached to this press release

Eric Wintemute, Chairman and CEO of American Vanguard, stated: “Our improved second quarter and mid-year performance reflects both external sales initiatives and internal management discipline. While the Ag Industry continues to experience strong headwinds, we are pleased with our ability to deliver revenue growth of 9% quarter-over-quarter and significantly increased net income. Top line improvement was driven by sales of our corn soil insecticides and Impact® post-emergent corn herbicide as well as higher sales of our non-crop products. Earnings rose as a result of higher gross profit margins attributable to improved manufacturing efficiency and favorable product mix.”

Mr. Wintemute added: “We continue to strengthen our balance sheet by focusing on carefully managing inventories and other working capital factors. Our strong cash generation has allowed us to reduce debt, enhancing our ability to grow through acquisition and pursue international initiatives, such as our recently announced Hong Kong based technology joint-venture.”

Mr. Wintemute concluded: “The balance of 2016 looks favorable with expected demand for our cotton products amidst this year’s 17% increase in domestic cotton acreage, our historically stable fumigant market and weather-dependent demand for our mosquito adulticide Dibrom. All-in-all, we had a solid quarter and will continue to build on that foundation over the course of the year. We look forward to telling you more during our conference call today.”


Conference Call

Eric Wintemute, Chairman & CEO, David Johnson, VP & CFO, and Bob Trogele, EVP & COO of AMVAC Chemical will conduct a conference call focusing on the financial results at 4:30 pm ET / 1:30 pm PT on Tuesday, August 2, 2016. Interested parties may participate in the call by dialing (201) 493-6744 - please call in 10 minutes before the call is scheduled to begin, and ask for the American Vanguard call. The conference call will also be webcast live via the News and Media section of the Company’s web site at www.american-vanguard.com. To listen to the live webcast, go to the web site at least 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, the conference call will be archived on the Company’s web site.

About American Vanguard

American Vanguard Corporation is a diversified specialty and agricultural products company that develops and markets products for crop protection and management, turf and ornamentals management and public and animal health. American Vanguard is included on the Russell 2000® and Russell 3000® Indexes as well as the S&P Small Cap 600 Index. To learn more about American Vanguard, please reference the Company’s web site at www.amvac-chemical.com.

The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in the conference call referenced in this release, all forward-looking statements are estimates by the Company’s management and are subject to various risks and uncertainties that may cause results to differ from management’s current expectations. Such factors include weather conditions, changes in regulatory policy and other risks as detailed from time-to-time in the Company’s SEC reports and filings. All forward-looking statements, if any, in this release represent the Company’s judgment as of the date of this release.

 

Company Contact:

  

Investor Representative

American Vanguard Corporation

  

The Equity Group Inc.

William A. Kuser, Director of Investor Relations

  

www.theequitygroup.com

(949) 260-1200

  

Lena Cati

williamk@amvac-chemical.com

  

Lcati@equityny.com (212) 836-9611


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

 

     For the three months
ended June 30
    For the six months
ended June 30
 
     2016     2015     2016     2015  

Net sales

   $ 72,724      $ 66,523      $ 142,198      $ 133,088   

Cost of sales

     41,329        41,402        83,300        83,317   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     31,395        25,121        58,898        49,771   

Operating expenses

     26,301        23,922        49,174        48,266   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

     5,094        1,199        9,724        1,505   

Interest expense

     462        662        1,003        1,303   
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before provision for income taxes and loss on equity investment

     4,632        537        8,721        202   

Income taxes expense (benefit)

     1,203        (393     2,263        (685
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before loss on equity investment

     3,429        930        6,458        887   

Less net loss from equity investment

     (47     (191     (129     (191
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     3,382        739        6,329        696   

Add back net loss (income) attributable to non-controlling interest

     (136     42        (289     136   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to American Vanguard

     3,246        781        6,040        832   
  

 

 

   

 

 

   

 

 

   

 

 

 

Earnings per common share—basic

   $ .11      $ .03      $ .21      $ .03   
  

 

 

   

 

 

   

 

 

   

 

 

 

Earnings per common share—assuming dilution

   $ .11      $ .03      $ .21      $ .03   
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average shares outstanding—basic

     28,893        28,676        28,851        28,602   
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average shares outstanding—assuming dilution

     29,377        29,202        29,342        29,103   
  

 

 

   

 

 

   

 

 

   

 

 

 


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

ASSETS

 

     June 30,
2016
    Dec. 31,
2015
 

Current assets:

    

Cash and cash equivalents

   $ 5,799      $ 5,524   

Receivables:

    

Trade, net of allowance for doubtful accounts of $363 and $423, respectively

     76,151        72,835   

Other

     3,394        2,554   
  

 

 

   

 

 

 

Total receivables

     79,545        75,389   

Inventories

     151,102        136,477   

Prepaid expenses

     13,979        11,172   

Income taxes receivable

     —         168   

Deferred income tax assets

     8,101        8,101   
  

 

 

   

 

 

 

Total current assets

     258,526        236,831   

Property, plant and equipment, net

     45,388        47,972   

Intangible assets, net of applicable amortization

     125,410        129,160   

Other assets

     30,331        29,576   
  

 

 

   

 

 

 
   $ 459,655      $ 443,539   
  

 

 

   

 

 

 
LIABILITIES AND STOCKHOLDERS’ EQUITY   

Current liabilities:

    

Current installments of other notes payable

   $ 18      $ 55   

Current installments of other liabilities

     138        514   

Accounts payable

     25,180        15,343   

Deferred revenue

     6,956        8,888   

Accrued program costs

     62,327        44,371   

Accrued expenses and other payables

     9,012        7,111   

Income taxes payable

     1,029        —    
  

 

 

   

 

 

 

Total current liabilities

     104,660        76,282   

Long-term debt and other notes payable, excluding current installments

     49,576        68,321   

Other liabilities, excluding current installments

     3,029        3,054   

Deferred income tax liabilities

     27,556        27,556   
  

 

 

   

 

 

 

Total liabilities

     184,821        175,213   
  

 

 

   

 

 

 

Commitments and contingent liabilities

    

Stockholders’ equity:

    

Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued

     —         —    

Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 31,788,644 shares at June 30, 2016 and 31,638,225 shares at December 31, 2015

     3,180        3,164   

Additional paid-in capital

     69,438        68,534   

Accumulated other comprehensive loss

     (3,993     (3,541

Retained earnings

     214,258        208,507   
  

 

 

   

 

 

 
     282,883        276,664   

Less treasury stock, at cost, 2,450,634 shares at June 30, 2016 and December 31, 2015

     (8,269     (8,269
  

 

 

   

 

 

 

American Vanguard Corporation stockholders’ equity

     274,614        268,395   

Non-controlling interest

     220        (69
  

 

 

   

 

 

 

Total stockholders’ equity

     274,834        268,326   
  

 

 

   

 

 

 
   $ 459,655      $ 443,539   
  

 

 

   

 

 

 


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

For The Six Months Ended June 30, 2016 and 2015

(Unaudited)

 

     2016     2015  

Cash flows from operating activities:

    

Net income

   $ 6,329      $ 696   

Adjustments to reconcile net income to net cash provided by operating activities:

    

Depreciation and amortization of fixed and intangible assets

     8,359        7,864   

Amortization of other long term assets

     2,358        2,734   

Amortization of discounted liabilities

     19        154   

Stock-based compensation

     1,068        2,485   

Tax benefit from exercise of stock options

     (47     (7

Operating loss from equity investment

     129        191   

Changes in assets and liabilities associated with operations:

    

(Increase) decrease in net receivables

     (4,156     8,975   

(Increase) decrease in inventories

     (14,625     397   

(Increase) decrease in prepaid expenses and other assets

     (2,661     143   

Decrease (increase) in income tax receivable/payable, net

     1,244        (878

Increase (decrease) in accounts payable

     9,837        (392

(Decrease) increase in deferred revenue

     (1,932     3,611   

Increase in program payables

     17,956        17,057   

Increase in other payables and accrued expenses

     1,612        794   
  

 

 

   

 

 

 

Net cash provided by operating activities

     25,490        43,824   
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Capital expenditures

     (1,729     (3,480

Investment

     (3,283     (125

Acquisitions of product lines and other intangible assets

     (224     (36,435
  

 

 

   

 

 

 

Net cash used in investing activities

     (5,236     (40,040
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Net payments under line of credit agreement

     (18,850     (11,120

Increase in other notes payable

     —         10,000   

Payments on other long-term liabilities

     (457     (899

Tax benefit from exercise of stock options

     47        7   

Payment of cash dividends

     —         (1,141

Net proceeds from sale of stock under ESPP and exercise of stock options

     (195     (40
  

 

 

   

 

 

 

Net cash used in financing activities

     (19,455     (3,193
  

 

 

   

 

 

 

Net increase in cash and cash equivalents

     799        591   

Cash and cash equivalents at beginning of period

     5,524        4,885   

Effect of exchange rate changes on cash

     (524     (387
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 5,799      $ 5,089